Background:

ScHARR has been commissioned by the UK National Screening Committee (NSC) to consider the cost effectiveness
and endoscopy capacity requirements of a variety of different screening options incorporating
faecal immunochemical testing (FIT) and bowel scope (BS) within the Bowel Cancer Screening Programme
(BCSP).

An existing cost-effectiveness model was used. The model was refined considerably, new data included and
model validation was undertaken. All FIT thresholds between 20 and 180 µg/ml were modelled. Analyses were
undertaken to determine which screening strategies involving repeated FIT screening and/or bowel scope are
most cost-effective given endoscopy constraints.
Note that the conclusions reached are based on optimising cost-effectiveness where effectiveness is measured
in terms of QALYs gained. If the aim was to optimise QALY gains or CRC incidence/mortality reduction then
conclusions would be different.

Note that the conclusions reached are based on optimising cost-effectiveness where effectiveness is measured
in terms of QALYs gained. If the aim was to optimise QALY gains or CRC incidence/mortality reduction then
conclusions would be different.